Abstract
Although cardiovascular disease (CVD) is recognised to be a condition that affects men more than women overall, this risks underplaying the significant challenges relating to the diagnosis and management of CVD in women. Women are adversely affected compared to men in terms of diagnosis, acute management and implementation of secondary prevention, and the evidence base for treating women is lacking, due to the low numbers of women included in trials. Hormonal fluctuations throughout a woman's lifetime can also affect CVD risk. GPNs are ideally placed to consider the challenges of recognising and addressing CVD risk in women and to support them with engaging in reducing their lifetime risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
